INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 2044
CLINICAL PICTURE AND FEATURES OF THE COURSE OF COMBINED
VIRAL HEPATITIS
Yuldashev Ya. M.
Department of infectious diseases,
Andijan State Medical Institute, Andijan, Uzbekistan
Abstract:
Viral hepatitis remains a significant global health challenge, with infections caused
by hepatitis A (HAV), B (HBV), C (HCV), D (HDV), and E (HEV) viruses. Co-infections with
two or more of these viruses are increasingly recognized as a critical clinical concern, often
leading to more severe liver disease, accelerated progression to cirrhosis and hepatocellular
carcinoma (HCC), and greater challenges in management compared to mono-infections. This
article reviews the clinical course and specific features of combined viral hepatitis infections.
We delve into the epidemiology, virological and immunological interactions, clinical
manifestations, diagnostic approaches, and treatment strategies for the most common and
clinically significant co-infection patterns, including HBV/HCV, HBV/HDV, and HAV/HEV.
The impact of underlying immunosuppression, particularly from concurrent HIV infection, on
the natural history of these co-infections is also discussed. Through a comprehensive review of
existing literature and data, this paper highlights the heightened morbidity and mortality
associated with viral hepatitis co-infections and underscores the necessity for integrated
screening, diagnosis, and management approaches to improve patient outcomes.
Keywords:
Viral Hepatitis, Co-infection, Hepatitis B Virus, Hepatitis C Virus, Hepatitis D
Virus, Liver Cirrhosis, Hepatocellular Carcinoma
INTRODUCTION
Viral hepatitis represents a spectrum of liver diseases caused by at least five distinct viruses:
Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis D
Virus (HDV), and Hepatitis E Virus (HEV). These infections pose a considerable global health
burden, contributing significantly to morbidity and mortality worldwide. While mono-infection
with any of these viruses can lead to a range of outcomes from acute, self-limiting illness to
chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC), the simultaneous infection
with two or more of these hepatotropic viruses presents a more complex and often more severe
clinical scenario.
The prevalence of viral hepatitis co-infections varies geographically, largely influenced by the
endemicity of each virus and the presence of shared transmission routes. For instance, HBV and
HCV co-infections are more common in regions where both viruses are highly prevalent and
among populations with high-risk behaviors such as intravenous drug use. Similarly, HDV, a
satellite virus that requires the presence of HBV for its replication, is a significant cause of
severe liver disease in areas endemic for HBV. Co-infections with enterically transmitted
viruses, such as HAV and HEV, can also occur, particularly in regions with poor sanitation, and
may lead to more severe acute hepatitis.
The clinical importance of viral hepatitis co-infection lies in the complex interactions between
the co-infecting viruses and the host immune system. These interactions can lead to a variety of
clinical outcomes, often characterized by a more aggressive disease course than that observed in
mono-infections. For example, co-infection with HBV and HCV has been associated with a
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 2045
higher likelihood of progressive liver fibrosis, a greater risk of developing HCC, and a more
complicated treatment response. The presence of one virus can influence the replication and
clinical expression of another. For instance, in HBV/HCV co-infection, HCV often suppresses
HBV replication, a phenomenon that can be reversed upon successful HCV treatment,
potentially leading to a flare of hepatitis B.
Furthermore, the management of patients with viral hepatitis co-infection is often more
challenging than that of mono-infected individuals. Diagnostic algorithms must be
comprehensive to identify all co-existing viral infections. Treatment decisions are complicated
by the need to consider the activity of each virus, the potential for drug-drug interactions, and
the risk of viral reactivation during therapy. The presence of underlying conditions, most
notably Human Immunodeficiency Virus (HIV) infection, further complicates the clinical
course and management, as it accelerates the progression of liver disease.
This review aims to provide a comprehensive overview of the clinical course and features of
combined viral hepatitis infections. It will explore the epidemiology, pathophysiology, clinical
presentations, and outcomes of the most significant co-infection patterns. Additionally, it will
discuss the current diagnostic and therapeutic strategies, highlighting the unique challenges and
considerations in managing these complex patients. A deeper understanding of the intricacies of
viral hepatitis co-infection is crucial for developing effective public health strategies and for
optimizing the clinical care of affected individuals.
MATERIALS AND METHODS
This scientific article is based on a comprehensive review of the existing medical and scientific
literature concerning viral hepatitis co-infections. A systematic search of prominent electronic
databases, including PubMed/MEDLINE, Scopus, and Google Scholar, was conducted for
relevant articles published up to June 2025. The search strategy employed a combination of
keywords and MeSH terms such as "viral hepatitis," "co-infection," "hepatitis B," "hepatitis C,"
"hepatitis D," "hepatitis A," "hepatitis E," "dual infection," "clinical course," "epidemiology,"
"pathogenesis," "treatment," and "outcomes."
The inclusion criteria for selected articles were: (1) original research articles, (2) systematic
reviews and meta-analyses, (3) clinical guidelines from major international societies (e.g.,
AASLD, EASL, WHO), and (4) case series that provided detailed clinical, virological, and
histological data on patients with viral hepatitis co-infection. Both English and Russian
language publications were considered to ensure a broad scope of evidence.
The collected data were critically appraised for their relevance, methodological quality, and
contribution to the understanding of the topic. Information was synthesized to construct a
narrative review structured according to the IMRaD format. The data for the tables were
extracted from systematic reviews, meta-analyses, and large cohort studies that provided
quantitative information on the prevalence of co-infections, comparative laboratory parameters,
and treatment outcomes.
The article is structured to provide a logical flow of information, starting with the broader
context of the problem (Introduction), followed by the presentation of synthesized data from the
literature (Results), a critical analysis and interpretation of these findings (Discussion), and
concluding with a summary of key points and recommendations for clinical practice and future
research (Conclusion and Recommendations). The references cited throughout the article were
managed and formatted according to the APA (7th edition) style.
RESULTS
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 2046
The synthesis of data from numerous studies reveals a consistent pattern of more severe disease
and poorer outcomes in patients with viral hepatitis co-infections compared to those with mono-
infections. The results are presented below, organized by the type of co-infection and including
summary tables.
Epidemiology of viral hepatitis Co-infections - The prevalence of viral hepatitis co-
infections demonstrates significant geographical and population-based variations. Table 1
provides an overview of the estimated prevalence of key co-infection types across different
WHO regions, highlighting the global burden of these dual infections. HBV/HCV co-
infection is notably prevalent in regions with high endemicity for both viruses, such as
parts of Asia and Africa. HDV co-infection is intrinsically linked to HBV prevalence, with
the highest rates observed in the Amazon Basin, parts of Africa, the Middle East, and
Central Asia.
Table 1: Estimated Prevalence of Viral Hepatitis Co-infections by WHO Region
WHO Region
HBV/HCV Co-infection (among
HBV-infected)
HBV/HDV Co-infection (among
HBV-infected)
Africa
1.5% - 20%
5% - 25%
Americas
2% - 10%
Up to 40% in the Amazon Basin
Eastern
Mediterranean
5% - 15%
10% - 20%
Europe
1% - 7% (higher in Eastern
Europe)
5% - 15% (higher in certain
regions)
South-East Asia
10% - 15%
Variable, with pockets of high
prevalence
Western Pacific
5% - 20%
Variable, with high rates in
Mongolia
Note: Data are synthesized from multiple epidemiological studies and systematic reviews.
Ranges reflect the heterogeneity of prevalence across different countries and risk groups within
each region.
Clinical and laboratory features of Co-infections - Patients with dual viral hepatitis
infections often present with more severe clinical and laboratory markers of liver disease
compared to their mono-infected counterparts. A comparative analysis of these
parameters is crucial for understanding the synergistic pathological effects of co-infecting
viruses.
Table 2: Comparative Clinical and Laboratory Findings in Mono-infected vs. Co-infected
Patients
Parameter
HBV Mono-
infection
HCV Mono-
infection
HBV/HCV
Co-
infection
HBV/HDV
Co-
infection
Serum ALT Levels
Often
elevated
Fluctuate
Often higher than
mono-infections
Markedly elevated,
especially
in
superinfection
Serum
Bilirubin
Levels
Usually
normal
in
Usually
normal
in
More likely to be
elevated
Often
elevated,
indicating
more
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 2047
chronic
phase
chronic
phase
severe inflammation
HBV DNA Levels
Variable
-
Often suppressed
by HCV
Often suppressed by
HDV
HCV RNA Levels
-
Variable
Can
be
the
dominant virus
-
Rate
of
Progression
to
Cirrhosis
Lower
Moderate
Significantly
higher
Highest among all
forms
of
viral
hepatitis
Risk
of
Hepatocellular
Carcinoma (HCC)
Increased
Increased
Synergistically
increased
Markedly increased
As shown in Table 2, co-infection generally leads to more pronounced liver inflammation
(higher ALT and bilirubin levels) and a more rapid progression to severe liver disease. In
HBV/HCV co-infection, a reciprocal inhibition of viral replication is often observed, with HCV
being the dominant virus in most cases. However, this does not translate to a milder disease
course; on the contrary, the risk of cirrhosis and HCC is substantially higher. HBV/HDV co-
infection represents the most aggressive form of chronic viral hepatitis, with a rapid progression
to cirrhosis and a high incidence of liver decompensation and HCC.
Clinical course of specific Co-infection types - HBV/HCV Co-infection: The clinical course
is variable and depends on which virus is dominant. In most cases, HCV suppresses HBV
replication, leading to low or undetectable HBV DNA levels. However, upon clearance of
HCV with direct-acting antivirals (DAAs), reactivation of HBV can occur, sometimes
leading to severe hepatitis flares. The risk of developing cirrhosis is 2-3 times higher in co-
infected individuals than in mono-infected patients.
HBV/HDV Co-infection: This can occur as a co-infection (simultaneous infection with both
viruses) or a superinfection (HDV infection in a chronic HBV carrier). Co-infection often
results in a severe acute hepatitis, which can be biphasic, but has a higher rate of spontaneous
clearance of both viruses. Superinfection, however, almost invariably leads to chronic HDV
infection, which is associated with a very rapid progression of liver disease. Cirrhosis can
develop within 5-10 years in a significant proportion of patients with chronic hepatitis D.
HAV/HEV Co-infection: Co-infection with these enterically transmitted viruses can lead to a
more severe form of acute hepatitis than either infection alone. While both are typically self-
limiting, co-infection has been associated with a higher risk of acute liver failure (ALF),
particularly in individuals with pre-existing chronic liver disease.
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 2048
Impact of HIV Co-infection - Concurrent HIV infection significantly worsens the
prognosis of viral hepatitis co-infections. The immunosuppression caused by HIV
accelerates the natural history of both HBV and HCV, leading to higher viral loads, a
faster progression to cirrhosis, and an increased risk of HCC. The management of triple-
infected patients (HIV/HBV/HCV) is particularly complex due to the potential for drug-
drug interactions between antiretroviral therapy (ART) and hepatitis treatments, as well
as the increased risk of hepatotoxicity.
Treatment Outcomes in Co-infections - The treatment of viral hepatitis co-infections
requires a tailored approach. Table 3 summarizes the general treatment strategies and
their efficacy in different co-infection scenarios.
Table 3: Treatment Strategies and Outcomes in Viral Hepatitis Co-infections
Co-
infection
Type
Primary
Treatment
Goal
Recommended Regimen
Sustained
Virological
Response
(SVR)
/
Control
Rate
Key Considerations and
Adverse Events
HBV/HCV
Eradication
of
HCV,
suppression
of HBV
Pan-genotypic
DAA
regimen for HCV. HBV
DNA monitoring and
initiation of nucleos(t)ide
analogues if needed.
>95% for
HCV SVR.
Risk
of
HBV
reactivation during or
after DAA therapy.
Regular monitoring of
liver function and HBV
DNA is crucial.
HBV/HDV
Suppression
of
HDV
replication
Pegylated interferon-alpha
(Peg-IFN-α) for at least
48 weeks. Bulevirtide is a
newer option.
25-30% for
Peg-IFN-α.
Higher
rates with
bulevirtide.
Peg-IFN-α
has
significant side effects
(flu-like
symptoms,
depression).
Relapse
after
treatment
is
common.
HIV/HBV
Suppression
of both HIV
and HBV
ART regimen including
two drugs active against
both
viruses
(e.g.,
tenofovir
+
lamivudine/emtricitabine).
High rates
of
viral
suppression
for
both
viruses.
Risk of HBV flare upon
discontinuation
of
HBV-active
ART.
Adherence is critical.
HIV/HCV
Eradication
of
HCV,
suppression
of HIV
DAA regimen for HCV
alongside effective ART.
>95% for
HCV SVR.
Potential for drug-drug
interactions
between
DAAs and some ART
agents.
Careful
selection of regimens is
required.
The advent of DAAs has revolutionized the treatment of HCV, with high cure rates also
observed in co-infected patients. However, the management of HBV/HDV co-infection remains
a challenge, with relatively low response rates to existing therapies.
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 2049
DISCUSSION
The findings presented in the results section unequivocally demonstrate that co-infection with
multiple hepatitis viruses significantly alters the clinical course of the disease, generally leading
to more severe outcomes. This discussion will delve into the implications of these findings, the
underlying mechanisms, and the challenges they pose for clinical management.
The epidemiological data underscores that viral hepatitis co-infection is not a rare occurrence
but a widespread public health issue. The overlapping modes of transmission for HBV, HCV,
and HDV create a fertile ground for dual and even triple infections, particularly in high-risk
populations. The significant prevalence of these co-infections necessitates integrated screening
programs. A patient diagnosed with one form of viral hepatitis, especially if acquired through
parenteral routes, should be systematically tested for other hepatotropic viruses. This is crucial
for accurate prognostication and for planning appropriate management strategies from the
outset.
The synergistic pathology observed in co-infected patients is a key area of concern. The
increased rates of progression to cirrhosis and the higher incidence of HCC in HBV/HCV and
HBV/HDV co-infections compared to mono-infections highlight the accelerated nature of liver
damage in these patients. The virological interactions, such as the suppression of HBV by HCV,
can be a "double-edged sword." While it may lead to lower HBV DNA levels, it does not confer
a protective effect. In fact, the immune-mediated liver injury may be more pronounced. The
reactivation of HBV upon HCV clearance is a critical clinical issue that has emerged with the
widespread use of highly effective DAAs. This necessitates a proactive approach to HBV
management in co-infected patients undergoing HCV treatment, including close monitoring and,
in many cases, prophylactic antiviral therapy for HBV.
For HBV/HDV co-infection, the clinical course is particularly aggressive. HDV superinfection
in a chronic HBV carrier is a major driver of rapid progression to end-stage liver disease. The
limited efficacy and significant side effects of the current standard of care, pegylated interferon-
alpha, have made the management of chronic hepatitis D a significant challenge. The recent
approval of bulevirtide, a viral entry inhibitor, in some regions offers a new hope for these
patients, although long-term data on its efficacy and safety are still emerging.
Co-infections involving the enterically transmitted viruses, HAV and HEV, while typically
acute and self-limiting, can be life-threatening, especially in individuals with pre-existing liver
disease. The increased risk of acute liver failure in these patients emphasizes the importance of
vaccination against HAV for all individuals with chronic liver conditions. While a vaccine for
HEV is not widely available, counseling on hygiene and food safety is paramount for these
patients.
The profound impact of HIV co-infection on the natural history of viral hepatitis cannot be
overstated. The accelerated progression of liver disease in triply infected individuals
(HIV/HBV/HCV) poses a formidable clinical challenge. Fortunately, the integration of potent
antiretroviral therapy, particularly regimens that are also active against HBV, has significantly
improved outcomes. However, the management of these patients requires a multidisciplinary
approach involving hepatologists and infectious disease specialists to navigate the complexities
of drug interactions and cumulative toxicities.
The data presented in the tables provide a quantitative dimension to these clinical observations.
The consistently higher biochemical markers of liver injury and the stark differences in long-
term outcomes between mono- and co-infected groups serve as a strong evidence base for the
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 2050
heightened severity of dual infections. The treatment outcome data, while promising for HCV
with the advent of DAAs, also highlight the unmet needs in the therapeutic armamentarium for
other co-infections, particularly HBV/HDV.
CONCLUSION
Co-infection with multiple viral hepatitis agents represents a distinct and more severe clinical
entity compared to mono-infection. The complex interplay between different viruses and the
host immune system leads to an accelerated progression of liver disease, a higher risk of
developing cirrhosis and hepatocellular carcinoma, and increased liver-related morbidity and
mortality. The clinical presentation and course vary depending on the specific combination of
viruses involved, with HBV/HDV co-infection being the most aggressive form. The presence of
underlying immunosuppression, particularly HIV, further exacerbates the disease course.
Effective management of patients with viral hepatitis co-infection hinges on comprehensive
screening for all hepatotropic viruses in at-risk individuals, accurate assessment of the stage of
liver disease, and a tailored therapeutic approach that considers the virological and clinical
activity of each infecting agent. While significant advances have been made in the treatment of
HCV, leading to high cure rates even in co-infected populations, the risk of HBV reactivation
remains a critical management consideration. The treatment of HBV/HDV co-infection
continues to be challenging, underscoring the need for novel therapeutic agents.
RECOMMENDATIONS
Based on the evidence reviewed, the following recommendations are proposed:
Universal Screening: All individuals diagnosed with an infection with one hepatitis virus (HBV,
HCV, or HDV) should be systematically screened for co-infections with other hepatotropic
viruses, as well as for HIV.
Comprehensive Baseline Assessment: Patients with co-infections should undergo a thorough
baseline evaluation, including quantification of viral loads for all active infections, assessment
of liver function, and non-invasive or invasive staging of liver fibrosis.
Proactive Management of HBV in Co-infections: In patients with HBV/HCV co-infection
undergoing DAA therapy for HCV, regular monitoring of HBV DNA and liver enzymes is
mandatory. Prophylactic nucleos(t)ide analogue therapy for HBV should be strongly considered
to prevent reactivation.
Specialized Care for HBV/HDV Co-infection: Patients with chronic hepatitis D should be
managed in specialized centers with expertise in this challenging condition. Enrollment in
clinical trials for new therapeutic agents should be encouraged.
Vaccination: All patients with chronic liver disease, including those with viral hepatitis co-
infections, should be vaccinated against HAV.
Integrated HIV and Hepatitis Care: Patients with HIV and viral hepatitis co-infections should
receive integrated care from a multidisciplinary team to optimize antiretroviral and hepatitis
treatment, manage drug interactions, and monitor for hepatotoxicity.
Future Research: Further research is needed to elucidate the precise molecular mechanisms of
viral interaction and immunopathogenesis in co-infections. There is also a pressing need for the
development of more effective and better-tolerated therapies for HBV/HDV co-infection.
INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE
ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal:
https://www.academicpublishers.org/journals/index.php/ijai
page 2051
References:
1. AASLD-IDSA. (2023). HCV Guidance: Recommendations for Testing, Managing, and
Treating Hepatitis C. Retrieved from
2. European Association for the Study of the Liver. (2017). EASL 2017 Clinical Practice
Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 67(2),
370-398.
3. European Association for the Study of the Liver. (2020). EASL Clinical Practice
Guidelines on hepatitis C virus (HCV): Recommendations on treatment of hepatitis C.
Journal of Hepatology, 73(5), 1219-1262.
4. Kushner, T., & Terrault, N. A. (2019). Management of hepatitis B and C virus coinfection.
Hepatology Communications, 3(9), 1147–1155.
5. Mavilia, M. G., & Wu, G. Y. (2018). The complex interplay of hepatitis B virus and
hepatitis C virus. Journal of Clinical and Translational Hepatology, 6(4), 412–422.
6. Olaru, C. P., et al. (2023). Global prevalence of hepatitis B or hepatitis C infection among
patients with tuberculosis disease: systematic review and meta-analysis. ResearchGate.
[Preprint].
7. Polaris Observatory HCV Collaborators. (2017). Global prevalence and genotype
distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet
Gastroenterology & Hepatology, 2(3), 161-176.
8. Rizzetto, M., & Ciancio, A. (2021). Hepatitis D. Cold Spring Harbor Perspectives in
Medicine, 11(8), a036928.
9. Soriano, V., et al. (2017). Management of HIV-HCV coinfection in the era of new oral
direct-acting antivirals. Expert Opinion on Drug Safety, 16(1), 5-16.
10. World Health Organization. (2017). Guidelines on hepatitis B and C testing. World Health
Organization.
11. World
Health
Organization.
(2021).
Hepatitis
D.
Retrieved
from
https://www.who.int/news-room/fact-sheets/detail/hepatitis-d
12. Yurdaydin, C. (2019). Recent advances in the management of hepatitis D. Hepatology
International, 13(2), 131–138.
